Virginia Oncology Associates

Clinical research site in Norfolk, Virginia · 6251 E VIRGINIA BEACH BLVD STE 200, NORFOLK, VA 23502-2824 · (757) 466-8683

Part of Virginia Oncology Associates

As of July 2026, 53 paid clinical trials are recruiting at Virginia Oncology Associates in Norfolk, Virginia. Active studies at this site cover conditions such as Breast Cancer, Multiple Myeloma and Non-Small Cell Lung Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Virginia Oncology Associates (53)

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

for Urothelial Cancer

74 locations incl. Fayetteville

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07421700·Phase 1, Phase 2·Recruiting·Listed Feb 2026

Apply to this trial

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

for Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma

61 locations incl. Los Angeles

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07392892·Phase 2, Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

for Non-small Cell Lung Cancer (NSCLC)

37 locations incl. Daphne

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07361497·Phase 3·Recruiting·Listed Jan 2026

Apply to this trial

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

29 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07266441·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

for Untreated, Unresectable, or Metastatic Colorectal Cancer

48 locations incl. Tucson

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07221357·Phase 2, Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

for Carcinoma, Transitional Cell

62 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07218380·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

for Metastatic Castration-resistant Prostate Cancer

34 locations incl. Goodyear

Sponsor: Amgen

Sex: Male·Age: 18+

Code: NCT07213674·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

for Metastatic Castration-resistant Prostate Neoplasms

53 locations incl. La Jolla

Sponsor: Janssen Research & Development, LLC

Sex: Male·Age: 18+

Code: NCT07164443·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

for Large B-cell Lymphoma

37 locations incl. Gilbert

Sponsor: Lyell Immunopharma, Inc.

Sex: All·Age: 18+

Code: NCT07188558·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

for HER2-positive Breast Cancer

22 locations incl. Long Beach

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: 18+

Code: NCT07102381·Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

for Breast Neoplasms

34 locations incl. Daphne

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT07060807·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

for Small-cell Lung Cancer

50 locations incl. Casa Grande

Sponsor: Amgen

Sex: All·Age: 18 - 99

Code: NCT07005128·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

for Breast Neoplasms

59 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06966700·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

for Early Breast Cancer

85 locations incl. Birmingham

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT05827081·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

for Triple-Negative Breast Cancer

81 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06393374·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

for PIK3CA Mutation

52 locations incl. Gilbert

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06982521·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

for Breast Cancer

134 locations incl. Daphne

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06966453·Phase 1, Phase 2·Recruiting·Listed May 2025

Apply to this trial

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

for Triple Negative Breast Neoplasms

37 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06841354·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for Large B-cell Lymphoma

60 locations incl. Gilbert

Sponsor: Allogene Therapeutics

Sex: All·Age: 18+

Code: NCT06500273·Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

for Non-Small Cell Lung Cancer

50 locations incl. Anchorage

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06793215·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

for High Grade Epithelial Ovarian Cancer

37 locations incl. Phoenix

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT05579366·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

for Carcinoma, Non-Small-Cell Lung

48 locations incl. Gilbert

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06623422·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

66 locations incl. Gilbert

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05552222·Phase 3·Recruiting·Listed Sep 2022

Apply to this trial

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

for Oligometastatic Prostate Cancer (OMPC)

40 locations incl. Fayetteville

Sponsor: Novartis Pharmaceuticals

Sex: Male·Age: 18 - 100

Code: NCT05939414·Phase 3·Recruiting·Listed Jul 2023

Apply to this trial

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

for Prostate Cancer

23 locations incl. Duarte

Sponsor: Amgen

Sex: Male·Age: 18+

Code: NCT04221542·Phase 1·Recruiting·Listed Jan 2020

Apply to this trial

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

for Relapsed Non-Hodgkin Lymphoma

32 locations incl. Irvine

Sponsor: Lyell Immunopharma, Inc.

Sex: All·Age: 18+

Code: NCT05826535·Phase 1, Phase 2·Recruiting·Listed Apr 2023

Apply to this trial

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

for Breast Cancer

49 locations incl. Mobile

Sponsor: Greenwich LifeSciences, Inc.

Sex: All·Age: 18 - 100

Code: NCT05232916·Phase 3·Recruiting·Listed Feb 2022

Apply to this trial

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

for Non Small Cell Lung Cancer

46 locations incl. Dothan

Sponsor: OncoC4, Inc.

Sex: All·Age: 18+

Code: NCT05671510·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

for Non-Small Cell Lung Cancer

76 locations incl. Phoenix

Sponsor: Summit Therapeutics

Sex: All·Age: 18+

Code: NCT05899608·Phase 3·Recruiting·Listed Jun 2023

Apply to this trial

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

38 locations incl. Birmingham

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06297226·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

for Leukemia, Myeloid, Acute

30 locations incl. Newport Beach

Sponsor: Sumitomo Pharma America, Inc.

Sex: All·Age: 12+

Code: NCT04988555·Phase 1, Phase 2·Recruiting·Listed Aug 2021

Apply to this trial

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

for Epithelial Ovarian Cancer

26 locations incl. Phoenix

Sponsor: TORL Biotherapeutics, LLC

Sex: Female·Age: 18+

Code: NCT06690775·Phase 2·Recruiting·Listed Nov 2024

Apply to this trial

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

for Urothelial Cancer

11 locations incl. Santa Barbara

Sponsor: Astellas Pharma Global Development, Inc.

Sex: All·Age: 18+

Code: NCT07566156·Phase 3·Recruiting·Listed May 2026

Apply to this trial

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

for Chronic Lymphocytic Leukemia (CLL)

20 locations incl. Duarte

Sponsor: Nurix Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07221500·Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

for Breast Cancer

20 locations incl. Duarte

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT07100106·Phase 1, Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

for Gastric Cancer

15 locations incl. New Haven

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06731478·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

for Colorectal Cancer

11 locations incl. Phoenix

Sponsor: Ono Pharmaceutical Co., Ltd.

Sex: All·Age: 18+

Code: NCT06948448·Phase 2·Recruiting·Listed Apr 2025

Apply to this trial

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

for Non-Small Cell Lung Cancer

11 locations incl. New Haven

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT05789082·Phase 1, Phase 2·Recruiting·Listed Mar 2023

Apply to this trial

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

for Relapsed and/or Refractory B-cell Lymphoma

17 locations incl. Gilbert

Sponsor: Kite, A Gilead Company

Sex: All·Age: 18+

Code: NCT04989803·Phase 1, Phase 2·Recruiting·Listed Aug 2021

Apply to this trial

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

for Metastatic Hormone-sensitive Prostate Cancer

21 locations incl. La Jolla

Sponsor: Novartis Pharmaceuticals

Sex: Male·Age: 18+

Code: NCT06991556·Phase 2·Recruiting·Listed May 2025

Apply to this trial

Showing the 40 most relevant of 53 recruiting trials at this site. Browse all with filters →

More research sites in Norfolk

Children's Hospital of The King's Daughters (41 trials)
Sentara Norfolk General Hospital (32 trials)
Clinical Trial Site (4 trials)
Eastern Virginia Medical School (4 trials)
Old Dominion University (4 trials)
Sentara Health (4 trials)
Sentara Health Research Center (4 trials)
Virginia Eye Consultants (4 trials)
Virginia Pediatric Eye Center (4 trials)
Virginia Oncology Associates (VOA) (4 trials)

Explore more

Paid clinical trials in Norfolk, VA · Virginia clinical trials